Journal of Clinical Trials
Open Access

Comparative immunohistochemical analysis of Beclin-1&MDM-2 in benign and malignant ameloblastomas

International Conference on Clinical Trials

July 27-29, 2015 Orlando-FL, USA

MA El-Barrawy, SA El-Barrawy, H S Raslan and SM El-Sheikh

Posters-Accepted Abstracts: J Clin Trials

Abstract :

Background: Ameloblastoma is the most frequently encountered neoplasma rising from the odontogenic epithelium. Beclin-
1protein plays a critical role in autophagy as a tumor suppressor gene. Whereas, the Murine Double Minute 2 (MDM-2) is a
cellular proto-oncogene capable if amplified of causing tumor-genesis. The expression and prognostic significance of both genes
are largely unexplored yet in this neoplasia. Therefore, the present investigation aimed to assess their possible biological role in
ameloblastomas.
Methods: This study was done among 35 studied cases: 29 cases of benign ameloblastomas and 6cases of ameloblastic carcinomas.
Labeled Streptavidin Biotin (LSAB+Dako) immunohistochemical method utilizing monoclonal antibodies for Beclin-1&MDM-2
genes was used.
Results: Most of the benign ameloblastomas showed intense total cell positivity for the Beclin-1while, the ameloblastic carcinomas
revealed mild to negative expression. Inversely, the MDM-2 oncoprotein demonstrated intense brown total cell reactivity in
amelobastic carcinoma and loss of the reaction to mild brown stain in benign ameloblastoma.
Conclusion: Based from these findings, one could conclude that MDM-2 could be a specific marker to identify the proliferative
activity, tumor aggressiveness and directly proportional with the degree of malignancy. In contrast, the high Beclin-1expression
could be a good indicator of prognosis in ameloblastomas. Hence, an overall comparison both studied genes may be very promising
molecular prognostic biomarkers.